Genital Diseases, Female  >>  carotuximab IV (ENV-105)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
carotuximab IV (ENV-105) / Kairos Pharma
NCT01381861: Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Completed
2
23
US
Carotuximab (TRC105), TRC105, NSC#754227
Tracon Pharmaceuticals Inc.
Recurrent Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
08/12
12/13

Download Options